Title of Invention: Therapy via targeted delivery of nanoscale particles Abstract: Disclosed are compositions, systems and methods for treating a subject's body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV. Detailed Description: TECHNICAL FIELD The present invention relates generally to targeted therapeutic compositions, systems and methods. Specifically, the invention pertains to compositions, systems and methods pertaining to devascularization using thermotherapy. In addition, the invention pertains to a combination of a thermotherapy method with at least one other treatment, where the targeted thermotherapy comprises the administration of an energy susceptive material, which is attached to a target-specific ligand, to a subject's body, body part, tissue, or body fluid, and the administration of energy from an energy source, so as to destroy or inactivate the target. BACKGROUND The time between the onset of disease in a patient and the conclusion of a successful course of therapy is often unacceptably long. Many diseases remain asymptomatic and evade detection while progressing to advanced, and often terminal, stages. In addition, this period may be marked by significant psychological and physical trauma for the patient due to the unpleasant side effects of even correctly prescribed treatments. Even diseases that are detected early may be most effectively treated only by therapies that disrupt the normal functions of healthy tissue or have other unwanted side effects. One such disease is cancer. Despite considerable research effort and some success, cancer is still the second leading cause of death in the United States, claiming more than 500,000 lives each year according to American Cancer Society estimates. Traditional treatments are invasive and/or are attended by harmful side effects (e.g., toxicity to healthy cells), often making for a traumatic course of therapy with only modest success. Early detection, a result of better diagnostic practices and technology, has improved the prognosis for many patients. However, the suffering that many patients must endure makes for a more stressful course of therapy and may complicate patient compliance with prescribed therapies. Further, some cancers defy currently available treatment options, despite improvements in disease detection. Of the many forms of cancer that still pose a medical challenge, prostate, breast, lung, and liver claim the vast majority of lives each year. Colorectal cancer, ovarian cancer, gastric cancer, leukemia, lymphoma, melanoma, and their metastases may also be life threatening. Conventional treatments for breast cancer, for example, typically include surgery followed by radiation and/or chemotherapy. These techniques are not always effective, and even if effective, they suffer from certain deficiencies. Surgical procedures range from removal of only the tumor (lumpectomy) to complete removal of the breast. In early stage cancer, complete removal of the breast may provide an assurance against recurrence, but is disfiguring and requires the patient to make a very difficult choice. Lumpectomy is less disfiguring, but can be associated with a greater risk of cancer recurrence. Radiation therapy and chemotherapy are arduous and are not completely effective against recurrence. Treatment of pathogen-based diseases is also not without complications. Patients presenting symptoms of systemic infection are often mistakenly treated with broad-spectrum antibiotics as a first step. This course of action is completely ineffective when the invading organism is viral. Even if a bacterium (e.g., E. coli) is the culprit, the antibiotic therapy eliminates not only the offending bacteria, but also benign intestinal flora in the gut that are necessary for proper digestion of food. Hence, patients treated in this manner often experience gastrointestinal distress until the benign bacteria can repopulate. In other instances, antibiotic-resistant bacteria may not respond to antibiotic treatment. Therapies for viral diseases often target only the invading viruses themselves. However, the cells that the viruses have invaded and “hijacked” for use in making additional copies of the virus remain viable. Hence, progression of the disease is delayed, rather than halted. For these reasons, it is desirable to provide improved and alternative techniques for treating disease. Such techniques should be less invasive and traumatic to the patient than the present techniques, and should only be effective locally at targeted sites, such as diseased tissue, pathogens, or other undesirable matter in the body. Preferably, the techniques should be capable of being performed in a single or very few treatment sessions (minimizing patient non-compliance), with minimal toxicity to the patient. In addition, the undesirable matter should be targeted by the treatment without requiring significant operator skill and input. Immunotherapy is a rapidly expanding type of therapy used for treating a variety of human diseases including cancer, for example. The FDA has approved a number of antibody-based cancer therapeutics. The ability to engineer antibodies, antibody fragments, and peptides with altered properties (e.g., antigen binding affinity, molecular architecture, specificity, valence, etc.) has enhanced their use in therapies. Cancer immunotherapeutics have made use of advances in the chimerization and humanization of murine antibodies to reduce immunogenic responses in humans. High affinity human antibodies have also been obtained from transgenic animals that contain many human immunoglobulin genes. In addition, phage display technology, ribosome display, and DNA shuffling have allowed for the discovery of antibody fragments and peptides with high affinity and low immunogenicity for use as targeting ligands. All of these advances have made it possible to design an immunotherapy that has a desired antigen binding affinity and specificity, and minimal immune response. The field of cancer immunotherapy makes use of markers that are over-expressed by cancer cells (relative to normal cells) or expressed only by cancer cells. The identification of such markers is ongoing and the choice of a ligand/marker combination is critical to the success of any immunotherapy. Immunotherapeutics fall into at least three classes: (1) deployment of antibodies that, themselves, target growth receptors, disrupt cytokine pathways, or induce complement or antibody-dependent cytotoxicity; (2) direct arming of antibodies with a toxin, a radionuclide, or a cytokine; (3) indirect arming of antibodies by attaching them to immunoliposomes used to deliver a toxin or by attaching them to an immunological cell effector (bispecific antibodies). Although armed antibodies have shown potent tumor activity in clinical trials, they have also exhibited unacceptably high levels of toxicity to patients. The disadvantage of therapies that rely on delivery of immunotoxins or radionuclides (i.e., direct and indirect arming) has been that, once administered to the patient, these agents are active at all times. These therapies often cause damage to non-tumor cells and present toxicity issues and delivery challenges. For example, cancer cells commonly shed surface-expressed antigens (targeted by immunotherapeutics) into the blood stream. Immune complexes can be formed between the immunotherapeutic and the shed antigen. As a result, many antibody-based therapies are diluted due to the interaction of the antibody with these shed antigens rather than interacting with the cancer cells, and thereby reducing the true delivered dose. Thus, a “therapy-on-demand” approach that minimizes adverse side effects and improves efficacy would be preferable. With thermotherapy, temperatures in a range from about 40° C. to about 46° C. (hyperthermia) can cause irreversible damage to disease cells. However, healthy cells are capable of surviving exposure to temperatures up to about 46.5° C. Elevating the temperature of individual cells in diseased tissue to a lethal level (cellular thermotherapy) may provide a superior treatment option. Pathogens implicated in disease and other undesirable matter in the body can also be destroyed via exposure to locally high temperatures. Hyperthermia may hold promise as a treatment for cancer and other diseases because it induces instantaneous necrosis (typically called “thermo-ablation”) and/or a heat-shock response in cells (classical hyperthermia), leading to cell death via a series of biochemical changes within the cell. State-of-the-art systems that employ microwave or radio frequency (RF) hyperthermia, such as annular phased array systems (APAS), attempt to tune energy for regional heating of deep-seated tumors. Such techniques are limited by the heterogeneities of tissue and to highly perfused tissue. This leads to the as-yet-unsolved problems of “hot spot” phenomena in untargeted tissue with concomitant underdosage in the desired areas. These factors make selective heating of specific regions with such systems very difficult. Another strategy that utilizes RF hyperthermia requires surgical implantation of microwave or RF based antennae or self-regulating thermal seeds. In addition to its invasiveness, this approach provides few (if any) options for treatment of metastases because it requires knowledge of the precise location of the primary tumor. The seed implantation strategy is thus incapable of targeting undetected individual cancer cells or cell clusters not immediately adjacent to the primary tumor site. Clinical success of this strategy is hampered by problems with the targeted generation of heat at the desired tumor tissues. SUMMARY OF THE INVENTION Hyperthermia for treatment of disease using energy sources exterior to the body has been recognized for several decades. However, a major problem has been the inability to selectively deliver a lethal dose of heat to the cells or pathogens of interest. In view of the above, there is a need for a thermotherapeutic method for treating diseased tissue, pathogens, or other undesirable matter that incorporates selective delivery of energy to a target within a subject's body, especially for devascularization. There is also a need for combined therapy methods for treating diseased tissue, pathogens, or other undesirable matter that include targeted thermotherapy. It is, therefore, an aspect of the present invention to provide a treatment method that involves the administration of energy susceptive materials that are attached to a target-specific ligand, to a subject's body, body part, tissue, or body fluid, and the administration of an energy source to inhibit or destroy the vascularity of the tumor (devascularization). It is also an aspect of the present invention to provide a treatment method that involves the administration of energy susceptive materials that are attached to a target-specific ligand, to a subject's body, body part, tissue, or body fluid, and the administration of an energy source to destroy, rupture, or inactivate the target (targeted thermotherapy) that can be utilized in combination with other treatments. It is another aspect of the present invention to administer the energy to a selected cell or tissue, to a subject's entire body, or extracorporeally to the subject's body, organ or body fluid. The present invention pertains to thermotherapy methods that comprise the administration of a bioprobe (energy susceptive particles that are attached to a target-specific ligand) to a subject, and administration of an energy source to the bioprobe, after a prescribed period of time for the bioprobe to locate and attach to a markered target, so as to destroy or inactivate the target or inhibit or destroy the vascularity of the tumor. The present invention also pertains to thermotherapy using the combination of targeted thermotherapy and at least one other treatment. The energy may be administered directly into the subject's body, body part, tissue, or body fluid (such as blood, blood plasma, blood serum, or bone marrow), or extracorporeally to the subject's body, organ or body fluid. The combination therapy methods of the present invention involve the thermotherapy methods and devices disclosed in commonly owned U.S. Patent Applications US2003/0032995, US2003/0028071, 10/360,578, and 10/360,561 (each of which is incorporated herein by reference) with at least one other treatment. The other treatments include, for instance, direct antibody therapy; hyperthermia heating which includes eddy current, RF, and microwave radiation, direct AC or DC currents, thermal seeds, thermal bath, non-targeted particle heating, and heating by ionizing radiation; radiation therapy which includes external beam radioimmuno therapy, internal radiotherapy, targeted isotopes, and radiation activated therapy; chemotherapy and pharmaceutical therapy, systemic or local delivery, local implanted delivery, antibody targeted, and light activated pharmaceuticals; photodynamic therapy (PDT); surgery and interventional techniques; bone marrow and stem cell transplantation; and medical imaging. The invention pertains to a targeted thermotherapy system for treating disease material in a patient. The system includes a bioprobe or a bioprobe system comprising a susceptor, an alternating magnetic field (AMF) inducing inductor that produces an AMF to energize the susceptor; and a generator coupled to the inductor to provide power to the AMF inducing inductor. The invention also pertains to therapeutic method for treating the body, body part, tissue, cell, or body fluid of a subject. The method comprises administering targeted thermotherapy to a target by supplying a bioprobe to the target and exposing the bioprobe to an alternating magnetic field (AMF), and administering at least one other therapy to the target. The at least one other therapy is administered prior to, during, after the targeted thermotherapy administration, or a combination thereof. The invention also pertains to a therapeutic method comprising administering targeted thermotherapy to a body, body part, or tissue of a subject containing a tumor, by supplying a bioprobe to the body, body part or tissue and exposing the bioprobe to an alternating magnetic field (AMF), and destroying or inhibiting the vascularity of the body, body part or tissue in response to exposure to the AMF. Further, the invention pertains to a therapeutic method for treating the body, body part, tissue, cell, or body fluid of a subject. The method comprises medically imaging the body, body part, tissue, cell or body fluid; and administering targeted thermotherapy by introducing a bioprobe to the body, body part, tissue, cell or body fluid of the subject and exposing the bioprobe to an alternating magnetic field (AMF). Administering the targeted thermotherapy occurs prior to, during, or after the medical imaging, or a combination thereof. The invention also pertains to a magnetic material composition. The composition comprises a particle having magnetic properties and forming a single magnetic domain; a biocompatible coating material for the particle; and a ligand selective to at least one disease material marker associated with disease material. The ligand can be i) bound to an uncoated portion of the particle, ii) bound to a coated portion of the particle, iii) bound to the particle and partially covered by the coating or iv) intercalated into the coating. In addition, the invention also relates to a magnetic material composition. The composition comprises a bioprobe, the bioprobe comprising a particle having magnetic properties associated with a first therapy, and a ligand selective to at least one disease material marker associated with a disease material; the ligand being associated with the particle The composition also comprises an agent associated with a second therapy, the agent being associated with the bioprobe. The above summary of the present invention is not intended to describe each illustrated embodiment or every implementation of the present invention. The figures and the detailed description that follow particularly exemplify these embodiments. BRIEF DESCRIPTION OF THE DRAWINGS The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which: FIG. 1 schematically illustrates a thermotherapy treatment system, according to an embodiment of the present invention; FIG. 2 schematically illustrates a thermotherapy treatment, according to an embodiment of the present invention; FIG. 3 schematically illustrates a bioprobe configuration, according to an embodiment of the present invention; FIG. 4 schematically illustrates a disease specific targeting ligand component of a bioprobe, according to an embodiment of the present invention; FIG. 5 schematically illustrates disease specific bioprobes bound to a disease cell surface, according to an embodiment of the present invention; FIG. 6 schematically illustrates a circuit for producing a thermotherapeutic alternating magnetic field, according to an embodiment of the present invention; FIG. 7 schematically illustrates a means for generating AMF, according to an embodiment of the present invention; FIG. 8 illustrates a cross sectional view of an inductor configuration, according to an embodiment of the present invention; FIG. 9 is a block diagram illustrating an embodiment of the targeted therapeutic system, according to an embodiment of the present invention; FIGS. 10a and 10b schematically illustrate two types of electrical field shielding for the inductor, according to an embodiment of the present invention; FIG. 11 schematically illustrates a bioprobe configuration comprising a radio tag, according to an embodiment of the present invention; and FIG. 12 schematically illustrates a bioprobe configuration comprising a chemotherapeutic agent, according to an embodiment of the present invention; While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims. DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS The present invention pertains to devices for treating diseased, disease-causing, or undesirable tissue or material, for use with magnetic material compositions and methods for treating or removing the tissue or material utilizing such devices. The therapeutic methods disclosed herein include the targeted delivery of nanometer sized magnetic particles to the desired or target material. 1. Definitions The term “bioprobe”, as used herein, refers to a composition comprising a susceptor and at least one ligand. The ligand acts to guide the bioprobe to a target. The term “disease material”, as used herein, refers to diseased, disease-causing, or undesirable material in the body or body part of a subject. The term “susceptor”, as used herein, refers to a particle (optionally comprising a coating) of a material that, when exposed to an energy source, either heats or physically moves. Similarly, the term “magnetic susceptor” refers to such particles wherein the energy source to which the particles respond is an alternating magnetic field (AMF). The term “ligand”, as used herein, refers to a molecule or compound that attaches to a susceptor (or a coating on the susceptor) and targets and attaches to a biological marker. A monoclonal antibody specific for Her-2 (an epidermal growth factor receptor protein) is an exemplary ligand. The term “target”, as used herein, refers to the matter for which deactivation, rupture, disruption or destruction is desired, such as a diseased cell, a pathogen, or other undesirable matter. A marker may be attached to the target. Breast cancer cells are exemplary targets. The term “marker”, as used herein, refers to an antigen or other substance to which the bioprobe ligand is specific. Her-2 protein is an exemplary marker. The term “bioprobe system”, as used herein, refers to a bioprobe specific to a target that is optionally identified via a marker. The term “indication”, as used herein, refers to a medical condition, such as a disease. Breast cancer is an exemplary indication. The term “energy source”, as used herein, refers to a device that is capable of delivering energy to the bioprobe's susceptor. The term “AMF” (an abbreviation for alternating magnetic field), as used herein, refers to a magnetic field that changes the direction of its field vector periodically, for example in a manner that is sinusoidal, triangular, or rectangular. The AMF may also be added to a static magnetic field, such that only the AMF component of the resulting magnetic field vector changes direction. It will be appreciated that an alternating magnetic field is accompanied by an alternating electric field and is electromagnetic in nature. The term “RF” (an abbreviation for radio frequency), as used herein, refers to a radio frequency in the range from about 0.1 Hz to about 900 MHz. The term “duty cycle”, as used herein, refers to the ratio of the time that the energy source is on to the total time that the energy source is on and off in one on-off cycle. The term “hyperthermia”, as used herein, refers to heating of tissue to temperatures between 40° C. and 45° C. The term “light”, as used herein, refers to ultra violet (UV) light, infrared (IR) light, or light at any other wavelength, or to light in laser form. The terms “targeted thermotherapeutic system”, “therapy system”, “targeted therapy”, “thermotherapy” and “therapy source”, as used herein, refer to the methods and devices that involve the targeted delivery of bioprobes for the treatment of an indication, including those disclosed in U.S. Patent Applications US2003/0032995, US2003/0028071, 10/360,578, and 10/360,561. It is to be understood that the singular forms of “a”, “an”, and “the”, as used herein and in the appended claims, include plural reference unless the context clearly dictates otherwise. 2. The Targeted Thermotherapeutic System The targeted thermotherapy system, an embodiment of which is illustrated in FIG. 1, includes an energy source, e.g., an alternating magnetic field (AMF) generator 101 for producing an alternating magnetic field that may be guided to a specific location within a patient 105 by a magnetic circuit 102. The therapeutic methods of the present invention may be performed following a determination of the presence of disease material in one or more areas of the patient. For example, the disease material may be any one or combination of cancers and cancerous tissue, a pathogenic infection (e.g., viral, bacterial or multicellular parasitic), toxin, or any pathogen-like material (e.g., a prion). The manner of making the diagnosis does not form part of the invention and may be performed using any standard method. However, the present invention, or aspects thereof, may be amenable to a diagnostic function alone or in conjunction with another method or apparatus. Such a diagnostic function may be performed by using a suitable technology or technique to interrogate the magnetic properties of the bioprobes, and thus evaluate their concentration and location within the patient. The location and concentration of bioprobes may each be determined using an existing technique, such as magnetic resonance imaging, or another diagnostic technique can be established and performed using a suitable magnetometer, such as a Superconducting Quantum Interference Device (SQUID). Information obtained from this interrogation may be used to define the parameters of treatment, i.e. the location, duration, and intensity of the alternating magnetic field. The patient may be positioned on an X-Y horizontal and vertical axis positioning bed 106. Bed 106 may be both horizontally and vertically positionable using a bed controller 108. In one embodiment of the present invention, the AMF generator produces an AMF in magnetic circuit 102 that exits the magnetic circuit at one pole face 104, passing through the air gap and the desired treatment area of the patient, and reenters the circuit through the opposing pole face 104, thus completing the circuit. An operator or medical technician is able to both control and monitor the AMF characteristics and bed positioning via a control panel 120. FIG. 2 illustrates a treatment of a patient with a device for treating disease material according to an embodiment of the present invention. The area of the patient to be treated 205 is localized in the region between the magnetic poles 204 using a positionable bed 206. This region may be any location of the patient including the chest, abdomen, head, neck, back, legs, arms, or any location of the skin. An AMF may be applied to treatment area 205 of the patient. The magnetic field, shown as lines of magnetic flux 212, interacts with both healthy and disease material in the localized area. Bioprobes 210, containing at least one appropriate ligand selective to the particular type of disease material, are bound to a disease material 214, or at least in the vicinity of the disease material. In the illustrated case, bioprobes 210 are selective to breast cancer. Bioprobes 210 become excited by the applied AMF and are inductively heated to a temperature sufficient to kill or render ineffective the disease material. For example, heat generated in the bioprobes 210 may pass to the cells, thereby causing the cells to die. Furthermore, poles 204 may be formed from pieces whose gap is adjustable, so as to permit other parts of the body to be treated. It is advantageous to set the gap between poles 204 to be sufficiently large to permit the part of the body containing the disease material to enter the gap, but not be so large as to reduce the magnetic field strength. Also shown are secondary coils 208 and optional cores 209. Any number of these secondary coils and optional cores may be added to modify the distribution of magnetic flux produced by the primary coils 208′ and the core between the poles 204. Secondary coils 208 may be wired in series or in parallel with the primary coils 208′, or they can be driven by separate AMF generators. The phase, pulse width and amplitude of the AMF generated by these coils may be adjusted to maximize the field strength in the gap, minimize the field strength in areas which may be sensitive to AMF, or to uniformly distribute the magnetic field strength in a desired manner. The targeted thermotherapy system may be used to administer a treatment to a subject intracorporeally (within the patient), extracorporeally (external to the patient), or a combination thereof. In extracorporeal therapy, bioprobes may be used to lyse, denature, or otherwise destroy the desired targets by circulating the blood outside of the body, exposing it to AMF, and returning it to the body. When the bioprobe/target complexes are carried primarily in the blood serum or plasma, the blood serum or plasma may be extracorporeally separated from the other blood components, exposed to AMF to destroy the target, and recombined with the other blood components before returning the blood to the body. The bioprobes may also be contained in a vessel or column through which the blood circulating outside of the body or the blood serum or plasma flows. The vessel or column may be exposed to AMF to destroy the targets before the blood is returned to the body. When the fluid is treated extracorporeally, the bioprobes may be introduced to the fluid after it has been extracted from the patient, or before extraction. 2.1 The Bioprobe of the Targeted Thermotherapy System FIG. 3 discloses a bioprobe configuration according to an embodiment of the present invention. A bioprobe 390 comprises a magnetic energy susceptive particle 342. The magnetic particle 342, also referred to as a susceptor, may include a coating 344. Coating 344 may fully or partially coat susceptor 342. At least one targeting ligand 340, such as, but not limited to, an antibody, may be located on an exterior portion of bioprobe 390. The targeting ligand 340 may be selected to seek out and attach to a target, such as a particular type of cell or disease matter. Heat is generated in the susceptor 342 when susceptor 342 is exposed to an energy source, such as AMF. Coating 344 may enhance the heating properties of bioprobe 390, particularly if coating 344 has a high viscosity, for example, is a polymeric material. In a general sense, this heat represents an energy loss as the magnetic properties of the material are forced to oscillate in response to the applied alternating magnetic field. The amount of heat generated per cycle of magnetic field and the mechanism responsible for the energy loss depend on the specific characteristics of both the susceptor 342 and the magnetic field. Susceptor 342 heats to a unique temperature, known as the Curie temperature, when subjected to an AMF. The Curie temperature is the temperature of the reversible ferromagnetic to paramagnetic transition of the magnetic material. Below this temperature, the magnetic material heats in an applied AMF. However, above the Curie temperature, the magnetic material becomes paramagnetic and its magnetic domains become unresponsive to the AMF. Thus, the material does not generate heat when exposed to the AMF above the Curie temperature. As the material cools to a temperature below the Curie temperature, it recovers its magnetic properties and resumes heating, as long as the AMF remains present. This cycle may be repeated continuously during exposure to the AMF. Thus, magnetic materials are able to self-regulate the temperature of heating. The temperature to which susceptor 342 heats is dependent upon, inter alia, the magnetic properties of the material, characteristics of the magnetic field, and the cooling capacity of the target site. Selection of the magnetic material and AMF characteristics may be tailored to optimize treatment efficacy of a particular tissue or target type. In an embodiment of the present invention, the magnetic material may be selected to possess a Curie temperature between about 40° C. and about 150° C. Many aspects of susceptor 342, such as material composition, size, and shape, directly affect heating properties. Many of these characteristics may be designed simultaneously to tailor the heating properties for a particular set of conditions found within a tissue type. For example, for susceptor 342, the most desirable size range depends upon the particular application and on the material(s) comprising susceptor 342. The size of susceptor 342 determines the total size of bioprobe 390. Bioprobes 390 that are to be injected may be spherical and may be required to have a long residence time in the bloodstream, i.e., avoid sequestration by the liver and other non-targeted organs. Bioprobe 390 may be successful in avoiding sequestration if its total diameter is less than about 30 nm. If bioprobe 390 contains a magnetite (Fe3O4) particle 342, then a diameter of susceptor 342 may be between about 8 nm and about 20 nm. In this case, bioprobes 390 may be sufficiently small to evade the liver, and yet the magnetic particle 342 still retains a sufficient magnetic moment for heating in an applied AMF. Magnetite particles larger than about 8 nm generally tend to be ferrimagnetic and thus appropriate for disease treatment. If other elements, such as cobalt, are added to the magnetite, this size range can be smaller. This results directly from the fact that cobalt generally possesses a larger magnetic moment than magnetite, which contributes to the overall magnetic moment of cobalt-containing susceptor 342. In general, the size of bioprobe 390 may be about 0.1 nm to about 250 nm, depending upon the disease indication and bioprobe composition. Examples of susceptors for use herein include iron oxide particles and FeCo/SiO2 particles. Some susceptors have a specific absorption rate (SAR) of about 310 Watts per gram of particle at 1,300 Oerstedt flux-density and 150 kHz frequency, such as series EMG700 and EMG1111 iron oxide particles of about 110 nm diameter available from Ferrotec Corp. (Nashua, N.H.). Other particles have a SAR of about 400 Watts per gram of particle under the same magnetic field conditions, such as the FeCo/SiO2 particles available from Inframat Corp. (Willington, Conn.). While determining the size of susceptor 342, its material composition may be determined based on the particular target. Because the self-limiting temperature of a magnetic material, or the Curie temperature, is directly related to the material composition, as is the total heat delivered, magnetic particle compositions may be tuned to different tissue or target types. This may be required because each target type, given its composition and location within the body, possesses unique heating and cooling capacities. For example, a tumor located within a region that is poorly supplied by blood and located within a relatively insulating region may require a lower Curie temperature material than a tumor that is located near a major blood vessel. Targets that are in the bloodstream will require different Curie temperature materials as well. Thus, in addition to magnetite, particle compositions may contain elements such as cobalt, iron, rare earth metals, etc. The presence of coating 344 and the composition of the coating material may form an integral part of the energy loss, and thus the heat produced, by bioprobes 390. In addition, coating 344 may serve additional purposes. The coating 344 does not have to cover the whole bioprobe core 342, but may only partially cover the core 342. Coating 344 may provide a biocompatible layer separating the magnetic material from the immunologic defenses in a patient, thereby controlling the residence time of the particles in the blood or tissue fluids. This control of residence time allows one to choose targeting ligands 340 that are best suited for a particular tissue type. In addition, coating 344 may serve to protect the patient from potentially toxic elements in susceptor 342. A second function of the coating materials may be the prevention of particle aggregation, as bioprobes 390 may be suspended in a fluid. It may be also be advantageous to coat bioprobe 390 with a biocompatible coating that is biodegradable or resorbable. In such an application, both the coating 344 and the susceptor 342 may be digested and absorbed by the body. Suitable materials for the coating 344 include synthetic and biological polymers, copolymers and polymer blends, and inorganic materials. Polymer materials may include acrylates, siloxanes, styrenes, acetates, alkylene glycols, alkylenes, alkylene oxides, parylenes, lactic acid, glycolic acid, and combinations thereof. Further suitable coating materials include a hydrogel polymer, a histidine-containing polymer, and a combination of a hydrogel polymer and a histidine-containing polymer. Coating materials may include biological materials such as polysaccharides, polyaminoacids, proteins, lipids, glycerols, fatty acids, and combinations thereof. Other biological materials for use as a coating material may include heparin, heparin sulfate, chondroitin sulfate, chitin, chitosan, cellulose, dextran, alginate, starch, carbohydrate, and glycosaminoglycan. Proteins may include an extracellular matrix protein, proteoglycan, glycoprotein, albumin, peptide, and gelatin. These materials may also be used in combination with any suitable synthetic polymer material. Inorganic coating materials may include any combination of a metal, a metal alloy, and a ceramic. Examples of ceramic materials include hydroxyapatite, silicon carbide, carboxylate, sulfonate, phosphate, ferrite, phosphonate, and oxides of Group IV elements of the Periodic Table of Elements. These materials may form a composite coating that also contains biological or synthetic polymers. Where susceptor 342 is formed from a magnetic material that is biocompatible, the surface of the particle itself operates as the biocompatible coating. The coating 344 material may also serve to facilitate transport of bioprobe 390 into a cell, a process known as transfection. Such coating materials, known as transfection agents, may include vectors, prions, polyaminoacids, cationic liposomes, amphiphiles, non-liposomal lipids, or any combination thereof. A suitable vector may be a plasmid, a virus, a phage, a viron, or a viral coat. The bioprobe coating may be a composite of a combination of transfection agents with organic and inorganic materials, such that the particular combination may be tailored for a particular type of a diseased cell and a specific location within a patient's body. To ensure that bioprobe 390 selectively attaches to, or otherwise associates with, the target, an appropriate ligand 340 may be combined with bioprobe 390. The association of a ligand or ligands with bioprobes 390 allows for targeting of cancer or disease markers on cells. It also allows for targeting biological matter in the patient The term ligand relates to compounds which may target molecules including, for example, proteins, peptides, antibodies, antibody fragments, saccharides, carbohydrates, glycans, cytokines, chemokines, nucleotides, lectins, lipids, receptors, steroids, neurotransmitters, Cluster Designation/Differentiation (CD) markers, imprinted polymers, and the like. Examples of protein ligands include cell surface proteins, membrane proteins, proteoglycans, glycoproteins, peptides, and the like. Example nucleotide ligands include complete nucleotides, complimentary nucleotides, and nucleotide fragments. Example lipid ligands include phospholipids, glycolipids, and the like. Ligand 340 may be covalently bonded to or physically interacted with susceptor 342 or coating 344. Ligand 340 may be bound covalently or by physical interaction to an uncoated portion of susceptor 342. Ligand 340 may be bound covalently or by physical interaction directly to an uncoated portion of susceptor 342 and partially covered by coating 344. Ligand 340 may be bound covalently or by physical interaction to a coated portion of bioprobe 390. Ligand 340 may be intercalated to the coated portion of bioprobe 390. Covalent bonding may be achieved with a linker molecule. The term “linker molecule”, as used herein, refers to an agent that targets particular functional groups on ligand 340 and on susceptor 342 or coating 344, and thus forms a covalent link between ligand 340 and susceptor 342 or coating 344. Examples of functional groups used in linking reactions include amines, sulfhydryls, carbohydrates, carboxyls, hydroxyls, and the like. The linking agent may be a homobifunctional or heterobifunctional crosslinking reagent, for example, carbodiimides, sulfo-NHS esters linkers, and the like. The linking agent may also be an aldehyde crosslinking reagent, such as glutaraldehyde. The linking agent may be chosen to link ligand 340 to susceptor 342 or coating 344 in a preferable orientation, specifically with the active region of the ligand 340 available for targeting. Physical interaction does not require that the linking molecule and ligand 340 be bound directly to susceptor 342 or to coating 344 by non-covalent means such as, for example, absorption, adsorption, or intercalation. FIG. 4 schematically illustrates an example of a ligand that may be used with an embodiment of the present invention. The ligand may be an antibody having a fragment crystallization (Fc) region 460 and fragment antigen binding (Fab) regions 472. Fab regions 472 may be the antigen binding regions of the antibody that include a variable light region 464 and a constant light region 466, along with a variable heavy region 468 and a constant heavy region 470. Biological activity of antibodies may be determined to a large extent by the Fc region 460 of the antibody molecule. Fc region 460 may include complement activation constant heavy chains 482 and macrophage binding constant heavy chains 484. Fc region 460 and Fab regions 472 may be connected by several disulfide linkages 462. Ligands that do not include the Fc region 460 may be preferable in order to avoid immunogenic response. Examples of these ligands may include antibody fragments, fragment antigen binding fragments (Fabs) 472, disulfide-stabilized variable region fragments (dsFVs) 474, single chain variable region fragments (scFVs) 480, recombinant single chain antibody fragments, and peptides. An antigen binding fragment (Fab) 472 may include a single Fab region 472 of an antibody. Single Fab region 472 may include a variable light 464 and a constant light region 466 bound to a variable heavy 468 and a constant heavy region 470 by a disulfide bond 462. A disulfide-stabilized variable region fragment (dsFV) 474 may include a variable heavy region 468 and a variable light region 464 of antibody joined by a disulfide bond. A leader sequence 476, which may be a peptide, may be linked to a variable light region 464 and variable heavy regions 468. Single chain variable region fragment (scFV) 480 may include a variable heavy region 468 and variable light region 464 of antibody joined by a linker peptide 478. A leader sequence 476 may be linked to the variable heavy region 468. Examples of ligand embodiments of the present invention may include, for example, polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, recombinant antibodies, bispecific antibodies, antibody fragments, scFVs 480, Fabs 472, dsFVs 474, recombinant single chain antibody fragments, peptides, and the like. Bispecific antibodies are non-natural antibodies that bind two different epitopes that are typically chosen on two different antigens. A bispecific antibody is typically comprised of two different fragment antigen binding regions (Fabs) 472. A bispecific antibody may be formed by cleaving an antibody into two halves by cleaving disulfide linkages 462 in Fc region 482 only. Two antibody halves with different Fab regions 472 are then combined to form a bispecific antibody with the typical “Y” structure. One or more ligands can be present in the bioprobe formulation. Antibodies of varying origin may be used according to this embodiment, provided they bind the target, although human, chimeric, and humanized antibodies may aid in avoiding the patient's immunogenic response. The choice of a marker (antigen) is useful in therapy utilizing bioprobes. For breast cancer and its metastases, a specific marker or markers may be chosen from cell surface markers such as, for example, members of the MUC-type mucin family, an epithelial growth factor (EGFR) receptor, a carcinoembryonic antigen (CEA), a human carcinoma antigen, a vascular endothelial growth factor (VEGF) antigen, a melanoma antigen (MAGE) gene, family antigen, a T/Tn antigen, a hormone receptor, growth factor receptors, a cluster designation/differentiation (CD) antigen, a tumor suppressor gene, a cell cycle regulator, an oncogene, an oncogene receptor, a proliferation marker, an adhesion molecule, a proteinase involved in degradation of extracellular matrix, a malignant transformation related factor, an apoptosis related factor, a human carcinoma antigen, glycoprotein antigens, DF3, 4F2, MGFM antigens, breast tumor antigen CA 15-3, calponin, cathepsin, CD 31 antigen, proliferating cell nuclear antigen 10 (PC 10), and pS2. For other forms of cancer and their metastases, a specific marker or markers may be selected from cell surface markers such as, for example, vascular endothelial growth factor receptor (VEGFR) family, a member of carcinoembryonic antigen (CEA) family, a type of anti-idiotypic mAB, a type of ganglioside mimic, a member of cluster designation/differentiation antigens, a member of epidermal growth factor receptor (EGFR) family, a type of a cellular adhesion molecule, a member of MUC-type mucin family, a type of cancer antigen (CA), a type of a matrix metalloproteinase, a type of glycoprotein antigen, a type of melanoma associated antigen (MAA), a proteolytic enzyme, a calmodulin, a member of tumor necrosis factor (TNF) receptor family, a type of angiogenesis marker, a melanoma antigen recognized by T cells (MART) antigen, a member of melanoma antigen encoding gene (MAGE) family, a prostate membrane specific antigen (PMSA), a small cell lung carcinoma antigen (SCLCA), a T/Tn antigen, a hormone receptor, a tumor suppressor gene antigen, a cell cycle regulator antigen, an oncogene antigen, an oncogene receptor antigen, a proliferation marker, a proteinase involved in degradation of extracellular matrix, a malignant transformation related factor, an apoptosis-related factor, and a type of human carcinoma antigen. In one embodiment of the present invention, the bioprobe attaches to, or associates with, cancer cells and is exposed to the AMF. Heat that is generated will destroy or otherwise deactivate immediately or over time (e.g., apoptosis) the cancer cells, which will be absorbed or otherwise removed from the body. In addition, cells that die by apoptosis will express and release heat shock proteins, such as HSP70, the presence of which can stimulate an immune reaction against any remaining cancer cells. Such a stimulated immune response may serve to protect the individual from future developments of cancer. In another embodiment, ligand 340 (FIG. 3) may be targeted to a predetermined target associated with a disease of the patient's immune system. The particular target and ligand 340 may be specific to, but not limited to, the type of the immune disease. Ligand 340 may have an affinity for a cell marker or markers of interest. The marker or markers may be selected such that they represent a viable target on T cells or B cells of the patient's immune system. The ligand 340 may have an affinity for a target associated with a disease of the patient's immune system such as, for example, a protein, a cytokine, a chemokine, an infectious organism, and the like. In another embodiment, ligand 340 may be targeted to a predetermined target associated with a pathogen-borne condition. The particular target and ligand 340 may be specific to, but not limited to, the type of the pathogen-borne condition. A pathogen is defined as any disease-producing agent such as, for example, a bacterium, a virus, a microorganism, a fungus, and a parasite. Ligand 340 may have an affinity for the pathogen or pathogen associated matter. Ligand 340 may have an affinity for a cell marker or markers associated with a pathogen-borne condition. The marker or markers may be selected such that they represent a viable target on infected cells. For a pathogen-borne condition, ligand 340 may be selected to target the pathogen itself. For a bacterial condition, a predetermined target may be the bacteria itself, for example, Escherichia coli or Bacillus anthracis. For a viral condition, a predetermined target may be the virus itself, for example, Cytomegalovirus (CMV), Epstein-Barr virus (EBV), a hepatitis virus, such as Hepatitis B virus, human immunodeficiency virus, such as HIV, HIV-1, or HIV-2, or a herpes virus, such as Herpes virus 6. For a parasitic condition, a predetermined target may be the parasite itself, for example, Trypanasoma cruzi, Kinetoplastid, Schistosoma mansoni, Schistosoma japonicum or Schistosoma brucei. For a fungal condition, a predetermined target may be the fungus itself, for example, Aspergillus, Cryptococcus neoformans or Rhizomucor. In another embodiment, the ligand 340 may be targeted to a predetermined target associated with an undesirable target. The particular target and ligand 340 may be specific to, but not limited to, the type of the undesirable target. An undesirable target is a target that may be associated with a disease or an undesirable condition, but also present in the normal condition. For example, the target may be present at elevated concentrations or otherwise be altered in the disease or undesirable state. Ligand 340 may have an affinity for the undesirable target or for biological molecular pathways related to the undesirable target. Ligand 340 may have an affinity for a cell marker or markers associated with the undesirable target. For an undesirable target, the choice of a predetermined target may be important to therapy utilizing bioprobes. Ligand 340 may be selected to target biological matter associated with a disease or undesirable condition. For arteriosclerosis, a predetermined target may be, for example, apolipoprotein B on low density lipoprotein (LDL). For obesity, a predetermined marker or markers may be chosen from cell surface markers such as, for example, one of gastric inhibitory polypeptide receptor and CD36 antigen. Another undesirable predetermined target may be clotted blood. In another embodiment, ligand 340 may be targeted to a predetermined target associated with a reaction to an organ transplanted into the patient. The particular target and ligand 340 may be specific to, but not limited to, the type of organ transplant. Ligand 340 may have an affinity for a biological molecule associated with a reaction to an organ transplant. Ligand 340 may have an affinity for a cell marker or markers associated with a reaction to an organ transplant. The marker or markers may be selected such that they represent a viable target on T cells or B cells of the patient's immune system. In another embodiment, ligand 340 may be targeted to a predetermined target associated with a toxin in the patient. A toxin is defined as any poison produced by an organism including, but not limited to, bacterial toxins, plant toxins, insect toxin, animal toxins, and man-made toxins. The particular target and ligand 340 may be specific to, but not limited to, the type of toxin. Ligand 340 may have an affinity for the toxin or a biological molecule associated with a reaction to the toxin. Ligand 340 may have an affinity for a cell marker or markers associated with a reaction to the toxin. In another embodiment, ligand 340 may be targeted to a predetermined target associated with a hormone-related disease. The particular target and ligand 340 may be specific to, but not limited to, a particular hormone disease. Ligand 340 may have an affinity for a hormone or a biological molecule associated with the hormone pathway. Ligand 340 may have an affinity for a cell marker or markers associated with the hormone disease. In another embodiment, the ligand 340 may be targeted to a predetermined target associated with non-cancerous diseased tissue. The particular target and ligand 340 may be specific to, but not limited to, a particular non-cancerous diseased tissue, such as non-cancerous diseased deposits and precursor deposits. Ligand 340 may have an affinity for a biological molecule associated with the non-cancerous diseased tissue. Ligand 340 may have an affinity for a cell marker or markers associated with the non-cancerous diseased tissue. In another embodiment, the ligand 340 may be targeted to a proteinaceous pathogen. The particular target and ligand 340 may be specific to, but not limited to, a particular proteinaceous pathogen. Ligand 340 may have an affinity for a proteinaceous pathogen or a biological molecule associated with the proteinaceous pathogen. Ligand 340 may have an affinity for a cell marker or markers associated with the proteinaceous pathogen. For prion diseases, also known as transmissible spongiform encephalopathies, a predetermined target may be, for example, Prion protein 3F4. Some exemplary embodiments of the bioprobe system, along with associated indications for which they may be utilized, are listed in Table I. TABLE I BIOPROBE SYSTEMS AND INDICATIONS BIOPROBE SYSTEM TARGET MARKER LIGAND INDICATION Endothelial cells of Integrin αvβ3 Ber EP4 antibody Metastatic breast cancer, metastatic growing blood LM609 antibody colon carcinoma vessels of Integrin antagonist metastatic cancer cells Cancer cells Unglycosylated DF3 Anti-DF3 antibody Breast cancer antigen Cancer cells Kallikreins Anti-kallikrein Ovarian and prostate cancer antibody Cancer cells ErbB2 (HER-2/neu) Anti-ErbB2 antibody, Breast and ovarian cancers and scFv (F5),
{'application_number': '<application-reference appl-type="utility">\n<document-id>\n<country>US</country>\n<doc-number>10696399</doc-number>\n<date>20031028</date>\n</document-id>\n</application-reference>', 'publication_number': '<publication-reference>\n<document-id>\n<country>US</country>\n<doc-number>20050090732</doc-number>\n<kind>A1</kind>\n<date>20050428</date>\n</document-id>\n</publication-reference>', 'source_file': './application/2005/ipa050428.xml', 'source_data': 'USPTO-Application'}